Zadik Z, Zung A
Pediatric Endocrine Unit, Kaplan Hospital, Rehovot, Israel.
Horm Res. 1997;48(6):274-7. doi: 10.1159/000185534.
Sixteen prepubertal children (10 males, 6 females) were treated with growth hormone (GH) 0.75 U/kg/week for 4-5 years until final height was attained. Before initiation of GH therapy height was below 2 SDS for age and gender, growth velocity was <4.5 cm/year, bone age was more than 2 SD below the mean for age, and the GH response to provocative tests was more than 10 microg/l. The final height of 9 patients exceeded their predicted and target heights. The final height of the treated patients was highly correlated with their siblings' heights (r = 0.806, p < 0.001) and to a lesser degree with the target or the predicted height (r = 0.401, p = 0.124 and r = 0.465, p = 0.06, respectively). It is concluded that the secular trend should be taken into consideration when evaluating the success of GH therapy.
16名青春期前儿童（10名男性，6名女性）接受了生长激素（GH）治疗，剂量为0.75 U/kg/周，持续4 - 5年，直至达到最终身高。在开始生长激素治疗前，身高低于年龄和性别的2个标准差，生长速度<4.5厘米/年，骨龄比年龄均值低2个标准差以上，并且生长激素对激发试验的反应>10微克/升。9名患者的最终身高超过了他们预测的和目标身高。接受治疗患者的最终身高与他们兄弟姐妹的身高高度相关（r = 0.806，p < 0.001），与目标身高或预测身高的相关性较小（分别为r = 0.401，p = 0.124和r = 0.465，p = 0.06）。结论是，在评估生长激素治疗的成功与否时应考虑长期趋势。
